Yang Bingqing, Fang Dan, Lv Qingyan, Wang Zhiqiang, Liu Yuan
College of Veterinary Medicine, Yangzhou University, Yangzhou, China.
Joint International Research Laboratory of Agriculture and Agri-Product Safety, The Ministry of Education of China, Yangzhou University, Yangzhou, China.
Front Pharmacol. 2021 May 12;12:673239. doi: 10.3389/fphar.2021.673239. eCollection 2021.
The emergence and rapid spread of antibiotic resistance in pathogenic bacteria constitute a global threat for public health. Despite ongoing efforts to confront this crisis, the pace of finding new potent antimicrobials is far slower than the evolution of drug resistance. The abuse of broad-spectrum antibiotics not only accelerates the formation of resistance but also imposes a burden on the intestinal microbiota, which acts a critical role in human homeostasis. As such, innovative therapeutic strategies with precision are pressingly warranted and highly anticipated. Recently, target therapies have achieved some breakthroughs by the aid of modern technology. In this review, we provide an insightful illustration of current and future medical targeted strategies, including narrow-spectrum agents, engineered probiotics, nanotechnology, phage therapy, and CRISPR-Cas9 technology. We discuss the recent advances and potential hurdles of these strategies. Meanwhile, the possibilities to mitigate the spread of resistance in these approaches are also mentioned. Altogether, a better understanding of the advantages, disadvantages, and mechanisms of action of these targeted therapies will be conducive to broadening our horizons and optimizing the existing antibacterial approaches.
病原菌中抗生素耐药性的出现和迅速传播对公共卫生构成了全球威胁。尽管人们一直在努力应对这一危机,但寻找新型强效抗菌药物的速度远远慢于耐药性的演变。广谱抗生素的滥用不仅加速了耐药性的形成,还对肠道微生物群造成负担,而肠道微生物群在人体稳态中起着关键作用。因此,迫切需要并高度期待精准的创新治疗策略。最近,借助现代技术,靶向治疗取得了一些突破。在本综述中,我们对当前和未来的医学靶向策略进行了深入阐述,包括窄谱药物、工程益生菌、纳米技术、噬菌体疗法和CRISPR-Cas9技术。我们讨论了这些策略的最新进展和潜在障碍。同时,也提到了在这些方法中减轻耐药性传播的可能性。总之,更好地了解这些靶向治疗的优缺点及作用机制将有助于拓宽我们的视野并优化现有的抗菌方法。